Bifogade filer
Kurs
+0,15%
Prenumeration
Kalender
Est. tid* | ||
2026-06-17 | 08:00 | Bokslutskommuniké 2026 |
2026-03-18 | 08:00 | Kvartalsrapport 2026-Q3 |
2025-12-18 | 08:00 | Kvartalsrapport 2026-Q2 |
2025-09-17 | N/A | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2025-09-16 | N/A | Årsstämma |
2025-09-11 | 08:00 | Kvartalsrapport 2026-Q1 |
2025-07-14 | N/A | Extra Bolagsstämma 2026 |
2025-06-18 | - | Bokslutskommuniké 2025 |
2025-03-13 | - | Kvartalsrapport 2025-Q3 |
2024-12-12 | - | Kvartalsrapport 2025-Q2 |
2024-09-18 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2024-09-17 | - | Årsstämma |
2024-09-12 | - | Kvartalsrapport 2025-Q1 |
2024-07-15 | - | Extra Bolagsstämma 2025 |
2024-06-18 | - | Bokslutskommuniké 2024 |
2024-03-14 | - | Kvartalsrapport 2024-Q3 |
2023-11-28 | - | Kvartalsrapport 2024-Q2 |
2023-09-06 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2023-09-06 | - | Kvartalsrapport 2024-Q1 |
2023-09-05 | - | Årsstämma |
2023-06-21 | - | Bokslutskommuniké 2023 |
2023-05-17 | - | Extra Bolagsstämma 2024 |
2023-03-16 | - | Kvartalsrapport 2023-Q3 |
2022-12-15 | - | Kvartalsrapport 2023-Q2 |
2022-11-07 | - | Extra Bolagsstämma 2022 |
2022-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2022-08-31 | - | Årsstämma |
2022-08-31 | - | Kvartalsrapport 2023-Q1 |
2022-06-16 | - | Bokslutskommuniké 2022 |
2022-03-15 | - | Kvartalsrapport 2022-Q3 |
2021-12-01 | - | Kvartalsrapport 2022-Q2 |
2021-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2021-08-31 | - | Årsstämma |
2021-08-31 | - | Kvartalsrapport 2022-Q1 |
2021-06-17 | - | Bokslutskommuniké 2021 |
2021-03-18 | - | Kvartalsrapport 2021-Q3 |
2020-12-03 | - | Kvartalsrapport 2021-Q2 |
2020-08-28 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2020-08-27 | - | Årsstämma |
2020-08-27 | - | Kvartalsrapport 2021-Q1 |
2020-06-12 | - | Bokslutskommuniké 2020 |
2020-03-12 | - | Kvartalsrapport 2020-Q3 |
2019-12-05 | - | Kvartalsrapport 2020-Q2 |
2019-08-30 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2019-08-29 | - | Årsstämma |
2019-08-29 | - | Kvartalsrapport 2020-Q1 |
2019-06-14 | - | Bokslutskommuniké 2019 |
2019-05-02 | - | Extra Bolagsstämma 2020 |
2019-03-21 | - | Kvartalsrapport 2019-Q3 |
2018-12-13 | - | Kvartalsrapport 2019-Q2 |
2018-08-31 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2018-08-30 | - | Årsstämma |
2018-08-30 | - | Kvartalsrapport 2019-Q1 |
2018-06-15 | - | Bokslutskommuniké 2018 |
2018-03-21 | - | Kvartalsrapport 2018-Q3 |
2017-12-19 | - | Kvartalsrapport 2018-Q2 |
2017-09-01 | - | X-dag ordinarie utdelning BIOVIC B 0.00 SEK |
2017-08-31 | - | Årsstämma |
2017-08-31 | - | Kvartalsrapport 2018-Q1 |
2017-06-14 | - | Bokslutskommuniké 2017 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Biovica today announces that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in San Diego, California. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations of quality, accuracy, and consistency, as outlined by CAP.
CAP accreditation offers several commercial advantages. It facilitates the process of obtaining reimbursement from private insurance providers and enables DiviTum® TKa expansion into New York, Maryland, and Washington D.C. Post license application and approval, Biovica will be able to offer DiviTum also in these locations and thereby be able to cover the entire US. In addition, CAP accreditation is a highly coveted credential, particularly among pharmaceutical and biotechnology companies. They seek it out when they require a more rigorous regulatory framework for their projects, especially when the data generated is intended for submission to the U.S. Food and Drug Administration (FDA).
"I take great pride in the efforts put forth by our team to reach this significant milestone. Attaining CAP accreditation underscores our unwavering commitment to quality.", says Warren Cresswell, President of the Americas at Biovica.
About CAP
The College of American Pathology (CAP) was founded in 1961 in the United States for laboratory quality control and is one of the world's most prestigious accreditation bodies. Through an application process, CAP reviews and accredits laboratories across the United States to ensure these laboratories meet certain safety and patient care criteria, helping laboratories maintain the accuracy of test results, ensuring accurate patient diagnosis, and meeting required standards from CLIA, FDA, and OSHA. CAP accreditation is known as the gold standard for laboratory quality control worldwide and ensures that quality control standards strict enough to conduct testing for clinical diagnostic purposes.
Contact
Anders Rylander, CEO
Phone: +46 76 666 16 47
E-mail: anders.rylander@biovica.com
Anders Morén, CFO
Phone: +46 73 125 92 46
E-mail: anders.moren@biovica.com
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com